Adjuvant chemotherapy is used to reduce the recurrence risk of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer; however, most patients with this condition are successfully treated with adjuvant hormone therapy alone without recurrence [1]. This evidence concerns the gene NR4A1 and breast cancer.